In this issue we have tried to bring together a series of reviews describing new developments in the pharmacologic management of schizophrenia. Important progress is being made not only in medication development, but also in furthering our ability to use available treatments and treatment combinations in the most effective manner. Topics discussed include: the role of blood levels; alternative somatic treatments for nonresponding patients; the role of clozapine; putative mechanisms of action of novel antipsychotics; an overview of potential antipsychotic drugs under development; new findings in maintenance treatment; a review of the impact of neuroleptic treatment on the long-term course of schizophrenia; and a discussion of obstacles which must be overcome to ensure that the promise of treatment research can be fully realized.